Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
Status:
Unknown status
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
In the setting of ST elevation myocardial infarction newer therapies has been recently
studied and, following encouraging results, introduced into the clinical practice. Prasugrel
showed to be a valid alternative to overcome limitation of clopidogrel therefore providing a
better ischemic protection. On the other hand, bivalirudin is at least as beneficial as
heparin/abciximab as anticoagulant agent but associated with fewer hemorrhagic events. The
primary hypothesis of the study is that the combination of prasugrel plus bivalirudin can be
associated with a better risk/benefit profile.
Phase:
Phase 4
Details
Lead Sponsor:
Istituto Clinico Sant'Ambrogio
Collaborators:
Azienda Ospedaliera Niguarda Cà Granda Centro Cardiologico Monzino Istituto Clinico Humanitas